SLC5A2 and type 2 diabetes mellitus: Table 3 describes a series of RCTs, including double-blind and multinational designs, that have investigated the efficacy of various SGLT2 inhibitors in patients with HFpEF, often including those with or without T2DM and chronic kidney disease (CKD).